Last reviewed · How we verify

NCT05683925

Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Characteristics in Parkinson's Disease

Completed NA Last updated 17 October 2023
What this trial tests

NA trial testing Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz in Parkinson Disease in 30 participants. Completed in 15 February 2023.

Timeline
1 September 2022
Primary endpoint
15 February 2023
15 February 2023

Quick facts

Lead sponsorUniversity Medical Centre Ljubljana
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment30
Start date1 September 2022
Primary completion15 February 2023
Estimated completion15 February 2023
Sites1 location across Slovenia

Drugs / interventions tested

Conditions studied

Sponsor

University Medical Centre Ljubljana

Who can join

18 and older, any sex, with Parkinson Disease or Gait Disorders, Neurologic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this randomised placebo-controlled trial, the investigators will include 30 PD (Parkinson's disease) patients with HY (Hoehn Yahr stage) \>2 and L-dopa unresponsive gait characteristics. Each participant will receive taVNS at 25Hz, taVNS at 100Hz and sham VNS (sVNS). During each stimulation, different gait characteristics will be measured with wearable insertion motion sensors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz

Trials testing the same drug.

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University Medical Centre Ljubljana trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05683925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing